We developed a rapid method to screen the efficacy of antimicrobial agents against Mycobacterium tuberculosis. A restriction fragment carrying a promoterless firefly luciferase gene was cloned into a 4,488-bp shuttle vector, pMV261, and luciferase was expressed under the control of a mycobacterial heat shock promoter. The resulting plasmid, pLUC10, was introduced by electroporation into the avirulent strain M. tuberculosis H37Ra. Luciferase assays of sonic lysates of Triton X-100-treated cells of M. tuberculosis H37Ra(pLUC10) yielded bioluminescence in excess of 1,000 relative light units/-109 tubercle bacilli, compared with 0.0025 for the same number of parental cells. A 48-h microdilution antimicrobial agent-screening assay using this strain was developed. One potentially useful approach to determining drug activity against mycobacteria is based on the use of a firefly luciferase reporter system, which has already proved useful in studying the metabolic activity and control of gene expression in other orfanisms (1, 13 (9) and the luciferase gene from pT3/T7-LUC (Clontech Laboratories, Palo Alto, Calif.). To construct pLUC10, pTB12 was first cleaved with BalI; HindIII linkers were added and then cleaved with HindIll and self-ligated to generate pTB29. The hsp6O promoter was then isolated as a 600-bp KpnI-HindIII fragment from pTB29 and inserted into KpnI-HindIll-cleaved pMV261 to generate pTB30. The 1.9-kbp HindIlI fragment from pT3/T7-LUC was then cloned into HindIII-digested pTB30. Finally, a clone carrying the luciferase gene in the proper orientation relative to the hsp60 promoter was designated pLUC10 (Fig. 1) . This plasmid (-6,400 bp) 
The number of reported cases of tuberculosis in the United States has shown a steady increase since 1988 (4) . In 1991, 26,283 new cases, representing an increase of approximately 18% from 1985, were reported to the Centers for Disease Control (4) . Outbreaks of tuberculosis caused by multidrug-resistant strains of Mycobacterium tuberculosis, especially among persons with human immunodeficiency virus infection, have also been reported (3, 10) . These trends underscore the need for improved methods for detection, identification, and antimicrobial susceptibility testing of clinical isolates of this species, as well as for improved methods for identifying new antituberculosis drugs.
One potentially useful approach to determining drug activity against mycobacteria is based on the use of a firefly luciferase reporter system, which has already proved useful in studying the metabolic activity and control of gene expression in other orfanisms (1, 13 (6), by using cells cultivated for 14 days in 50 ml of complete Middlebrook 7H9 broth and treated with 1 mg of D-cycloserine per ml for 16 h before harvesting. Luciferase assays. Ten milliliters of stationary-phase (21-day) culture in Middlebrook complete 7H9 broth (supplemented with 0.05% Tween 80 and 10 ,ug of kanamycin per ml) was centrifuged (12,000 x g, 10 min, 4°C), and 10 mg of the pellet was resuspended in 1 ml of the same broth to give a concentration of -109 tubercle bacilli. Tenfold dilutions of these suspensions were made in broth, and 1 ml of each was centrifuged (12,000 x g, 4°C, 10 min) in 1.5-ml conical polypropylene tubes. The pellets were washed in phosphatebuffered saline (pH 7.2) and resuspended in 100 pl of a detergent lysis buffer (1% Triton X-100, 25 mM Tris [pH 7.8 with H3P04], 10 mM trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), 10 mM dithiothreitol, 50% glycerol) supplied in a commercial luciferase assay system (Promega Corp.). These suspensions were sonicated for 5 min (5-s cycles at a 60% pulse) with a 431A cuphorn attachment on a W-380 cell disruptor (Heat Systems-Ultrasonics, Farmingdale, N.Y.), cooled to 0°C with a circulating solution of 50% methanol, and then dispensed into 96-well microdilution plates (flat bottom, white; Microlite 2; Dynatech Laboratories, Inc., Chantilly, Va.). Direct freezethaw microdilution plate lysis was performed in a similar manner, except that 100 ,ul of the unwashed cell dilutions, followed by 100 ,ul of Promega lysis buffer, was placed directly into microdilution plates, which were incubated at -70°C for 30 min, and then thawed at room temperature. 
RESULTS
A map of plasmid pLUC10 linearized at its unique KpnI site is shown in Fig. 1 . The 1,900-bp HindIlI fragment containing the firefly luciferase gene and the hsp6O promoter was inserted into shuttle vector pMV261 (Fig. 1) Results of conventional macrodilution and microdilution susceptibility testing of M. tuberculosis H37Ra and H37Ra(pLUC10) are shown in Table 2 . MICs varied by no more than 1 drug concentration for each of the six drugs tested by both methods. As previously reported (12) , however, microdilution MICs varied by inoculum size for three drugs (kanamycin, streptomycin, and ethambutol). As expected, strain H37Ra(pLUC10) was kanamycin resistant (MIC, 32 to 64 ,ug/ml) because of the 3'-aminoglycoside phosphotransferase production encoded on plasmid pLUC10.
Luciferase susceptibility testing of nine drugs was performed by the freeze-thaw lysis method (Table 3) . Bioluminescence readings after 2, 7, and 14 days were <20 x RLU for the lowest concentration tested (0.06 ,ug/ml) for streptomycin, isoniazid, rifabutin, and rifampin. For 
